2009年7月
A two-stage case-control association study of PADI2 with schizophrenia
JOURNAL OF HUMAN GENETICS
- 巻
- 54
- 号
- 7
- 開始ページ
- 430
- 終了ページ
- 432
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1038/jhg.2009.52
- 出版者・発行元
- NATURE PUBLISHING GROUP
Peptidylarginine deiminases (PADIs), five isoforms of which have been identified, catalyze the conversion of arginine residues to citrulline residues in proteins. Recent studies have revealed that abnormal activation of PADI2, the gene for which is expressed throughout the nervous system, is likely to be related to the pathogenesis of neuropsychiatric diseases with neurodegenerative processes, such as Alzheimer's disease and multiple sclerosis. Such a progressive neurodegenerative process could be involved in the etiology and/or course of schizophrenia, and PADI2 may be a candidate gene for schizophrenia. To assess whether PADI2 has a role in vulnerability to schizophrenia, we conducted a two-stage case-control association study in Japanese individuals. In a screening population of 534 patients and 559 control individuals, we examined eight single-nucleotide polymorphisms (SNPs) including four haplotype tag SNPs and four coding SNPs in PADI2. There was a potential association of a synonymous SNP in exon 7 with schizophrenia. However, we could not replicate this association in a confirmatory population of 2126 patients and 2228 control individuals. The results of this study suggest that PADI2 does not contribute to genetic susceptibility to schizophrenia. Journal of Human Genetics (2009) 54, 430-432; doi: 10.1038/jhg.2009.52; published online 29 May 2009
- リンク情報
- ID情報
-
- DOI : 10.1038/jhg.2009.52
- ISSN : 1434-5161
- PubMed ID : 19478818
- Web of Science ID : WOS:000268314100012